ReviewJournal of immunology research2026
P2 Receptors as Therapeutic Targets in Allergic Rhinitis: Insights From the Use of Natural Products and Preclinical Studies.
Review in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Allergic rhinitis (AR) is a chronic inflammatory disorder of the upper airways that is mediated by immunoglobulin E (IgE) and triggered by environmental allergens. Current pharmacological therapies, including antihistamines, corticosteroids, and immunotherapy, offer symptomatic relief but are limited by their incomplete disease-modulating effects and potential adverse side effects. Purinergic P2 receptors (P2Rs; P2X and P2Y subtypes) have emerged as key modulators of allergic inflammation and regulate mast cell degranulation, T helper 2 (Th2) cytokine release, eosinophil recruitment, and NLRP3 inflammasome activation. Natural products, including polyphenols, flavonoids, terpenoids, and alkaloids, demonstrate multitarget anti-inflammatory effects and have the potential to modulate P2R signaling. However, direct evidence of their activity on P2Rs in AR remains limited. This review critically summarizes the immunopathology of AR, highlights the functional relevance of P2Rs, and discusses emerging natural product-based strategies, emphasizing mechanistic insights and translational potential for the development of novel therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.